Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Other Non Operating Income: 2010-2025

Historic Other Non Operating Income for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Sep 2025 value amounting to $5.3 million.

  • Arrowhead Pharmaceuticals' Other Non Operating Income rose 249.33% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 million, marking a year-over-year increase of 400.86%. This contributed to the annual value of $5.3 million for FY2025, which is 400.86% up from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its Other Non Operating Income stood at $5.3 million for FY2025, which was up 400.86% from -$1.7 million recorded in FY2024.
  • Arrowhead Pharmaceuticals' Other Non Operating Income's 5-year high stood at $5.3 million during FY2025, with a 5-year trough of -$1.7 million in FY2024.
  • For the 3-year period, Arrowhead Pharmaceuticals' Other Non Operating Income averaged around $1.7 million, with its median value being $1.5 million (2023).
  • In the last 5 years, Arrowhead Pharmaceuticals' Other Non Operating Income skyrocketed by 455.06% in 2021 and then tumbled by 213.65% in 2024.
  • Arrowhead Pharmaceuticals' Other Non Operating Income (Yearly) stood at $2.1 million in 2021, then slumped by 63.04% to $765,000 in 2022, then soared by 101.05% to $1.5 million in 2023, then tumbled by 213.65% to -$1.7 million in 2024, then spiked by 400.86% to $5.3 million in 2025.